Abstract:Background: The goal of this study was to report a fully automated radiosynthetic procedure of a novel tau tracer [ 18 F]-S16 and its safety, biodistribution, and dosimetry in healthy volunteers as well as the potential utility of [ 18 F]-S16 positron emission tomography (PET) in Alzheimer’s disease (AD). Methods: The automated radiosynthesis of [ 18 F]-S16 was performed on a GE Tracerlab FX2 N module. For the biodistribution and dosimetry study, healthy volunteers underwent a series of PET scans acquired at 10, 60, 120, and 240 min post-injection. The biodistribution and safety were assessed. For the AD study, both AD and healthy controls (HCs) underwent dynamic [ 18 F]-S16 and static [ 18 F]-FDG PET imaging. [ 18 F]-S16 binding was assessed quantitatively using standardized uptake value ratios (SUVRs) measured at different regions of interest (ROIs). [ 18 F]-S16 SUVRs were compared between the AD patients and HCs using the Mann–Whitney U -test. In AD patients with all cortical ROIs, Spearman rank-correlation analysis was used to calculate the voxel-wise correlations between [ 18 F]-S16 and [ 18 F]-FDG. Results: The automated radiosynthesis of [ 18 F]-S16 was finished within 45 min, with a radiochemical yield of 30 ± 5% ( n = 8, non-decay-corrected). The radiochemical purity was greater than 98%, and the specific activity was calculated to be 1,047 ± 450 GBq/μmol ( n = 5), and [ 18 F]-S16 was stable in vitro . In the healthy volunteer study, no adverse effect was observed within 24 h post-injection, and no defluorination was observed in vivo . The radiotracer could pass through the blood–brain barrier easily and was rapidly cleared from the circulation and excreted through the hepatic system. The whole-body mean effective dose was 15.3 ± 0.3 μSv/MBq. In AD patients, [ 18 F]-S16 accumulation was identified as involving the parietal, temporal, precuneus, posterior cingulate, and frontal lobes. No specific [ 18 F]-S16 cerebral uptake was identified in HCs. The SUVR of AD patients was significantly higher than that of HCs. No specific binding uptake was found in the choroid plexus, venous sinus, and white matter. A significant correlation was found between [ 18 F]-S16 binding and hypometabolism across neocortical regions. Conclusion: [ 18 F]-S16 could be synthesized automatically, and it showed favorable biodistribution and safety in humans. [ 18 F]-S16 PET indicated a high image quality for imaging tau deposition in AD and distinguishing AD from HCs.

Evaluating Ga68 Regional Distribution as a New Pet Tracerfor Diagnosis Cerebral Amyloid Angiopathy

Evaluating [68Ga]ga-P14-032 As a Novel PET Tracer for Diagnosis Cerebral Amyloid Angiopathy

68Ga-Labeled Benzothiazole Derivatives for Imaging Aβ Plaques in Cerebral Amyloid Angiopathy

Evaluation of a novel PET tracer [18F]-Florbetazine for Alzheimer's disease diagnosis and β-amyloid deposition quantification

Study Of Tau Deposition In Patients Of Alzheimer'S Disease With [F-18]-Apn-1607 Pet Tracer And Its Relationship With Cerebral Glucose Metabolism

A Near-infrared Fluorescence and Positron Emission Tomography Bimodal Probe for in Vivo Imaging of Amyloid-β Species.

Novel β-amyloid PET Imaging Study of [ 18 F]92 in Patients with Cognitive Decline

Preparation, biological characterization and preliminary human imaging studies of 68Ga-DOTA-IBA

Synthesis and Evaluation of a Novel PET Radioligand for Imaging Glutaminyl Cyclase Activity as a Biomarker for Detecting Alzheimer's Disease

Feasibility of 68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Light-Chain Cardiac Amyloidosis

[18F]-D3FSP β-amyloid PET imaging in older adults and alzheimer's disease

Feasibility and kinetic characteristics of (68)Ga-NOTA-RGD PET for in vivo atherosclerosis imaging

Biodistribution and Dosimetry Evaluation for a Novel Tau Tracer [18F]-S16 in Healthy Volunteers and Its Application in Assessment of Tau Pathology in Alzheimer’s Disease

Glial reactivity in a mouse model of beta-amyloid deposition assessed by PET imaging of P2X7 receptor and TSPO using [11C]SMW139 and [18F]F-DPA

Synthesis and preclinical evaluation of diarylamine derivative as Tau-PET radiotracer for Alzheimer's Disease

The Imaging Features and Clinical Associations of a Novel Tau PET Tracer—18F-APN1607 in Alzheimer Disease

18F-Florbetaben PET/CT for the Diagnosis and Subtyping of Cardiac Amyloidosis: A Case Series and Review of the Literature

Imaging Brain Amyloid of Alzheimer Disease in Vivo in Transgenic Mice with an Aβ Peptide Radiopharmaceutical

The biodistribution and imaging of a novel amyloid probe 131I-serum amyloid P-component in mice model of amyloidosis

Head-to-head comparison of [18F]florbetapir and [18F]FDG PET for the early detection of amyloidosis in systemic amyloidosis and plasma cell dyscrasias

Associations of [18F]-APN-1607 Tau PET Binding in the Brain of Alzheimer’s Disease Patients With Cognition and Glucose Metabolism